Aficamten

阿夫凯泰

Report date: 2026/03/16 20:01:47
NME

Base Information

Drug NameAficamten
Drug Alias Name星舒平MYQORZOCK-3773274CK-274BAY-3723113
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCardiac myosin inhibitors
TargetsCardiac myosin
Therapy Area/IndicationsCardiomyopathy, Hypertrophic, FamilialCardiomyopathy, Hypertrophic
Global Approved IndicationsCardiomyopathy, Hypertrophic
Approved Indications in ChinaCardiomyopathy, Hypertrophic
Original Approved Country/TerritoryMainland China
Original Approved Date2025/12/16
Country/TerritoryCzechiaCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCytokinetics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytokinetics Ireland LtdRoyalty Pharma PLCSanofi +[8] 
Inactive CompaniesCorxel Pharmaceuticals Inc
Active IndicationsCardiomyopathy, Hypertrophic, FamilialCardiomyopathy, Hypertrophic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG